Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Outcomes From COACH Trial Evaluating TransCon CNP and Progress Hormone in Achondroplasia January 8, 2026 4:30 PM EST
Firm Members
Scott Smith – CFO, Government VP & Member of Government Board
Jan Mikkelsen – President, CEO, Member of Government Board & Government Director
Aimee Shu – Government VP & Chief Medical Officer
Convention Name Members
Tazeen Ahmad – BofA Securities, Analysis Division
Joseph Schwartz – Leerink Companions LLC, Analysis Division
Li Wang Watsek – Cantor Fitzgerald & Co., Analysis Division
Gabriella Garr – TD Cowen, Analysis Division
Maxwell Skor – Morgan Stanley, Analysis Division
Kyuwon Choi – Goldman Sachs Group, Inc., Analysis Division
Gavin Clark-Gartner – Evercore ISI Institutional Equities, Analysis Division
Yun Zhong – Wedbush Securities Inc., Analysis Division
Alexander Thompson – Stifel, Nicolaus & Firm, Included, Analysis Division
Luca Issi – RBC Capital Markets, Analysis Division
Derek Archila – Wells Fargo Securities, LLC, Analysis Division
Presentation
Operator
Thanks for standing by, and welcome to Ascendis Pharma’s Section II COACH trial high line week 52 information Name. [Operator Instructions]
I’d now like handy the decision over to Scott Smith, Ascendis Pharma’s CFO. Please go forward.
Scott Smith
CFO, Government VP & Member of Government Board
Thanks a lot, operator, and thanks, everybody, for becoming a member of us on as we speak’s name. Becoming a member of me are Jan Moller Mikkelsen, President and Chief Government Officer; and Aimee Shu, Government Vice President of Endocrine and Uncommon Illness Medical Sciences and Chief Medical Officer.
Earlier than we start, I wish to remind you that this presentation will comprise forward-looking statements which are meant to be coated underneath the protected harbor supplied by the Personal Securities Litigation Reform Act. Examples of such statements could embrace, however aren’t restricted to, statements relating to our continued improvement of TransCon CNP and TransCon Progress Hormone mixture therapy, our pipeline candidates and expectations with
